TargetCancer Foundation (TCF) proudly announced today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial that brings advances in precision medicine to people living with rare cancers and their treating physicians, right in their own communities.
Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.
May 19, 2020 is OVAC Lobby Day highlights its work delivering a unified message to Congress and the White House on the need for increased cancer-related appropriations. Held virtually this year due to the COVID-19 pandemic, these requests affect millions of Americans facing cancer each day.
Medicamentos actuales y emergentes “Existen muchas opciones terapéuticas disponibles, pero sigue siendo un desafío hacer coincidir el medicamento correcto con el paciente correcto” Recuerdo en mi memoria ... es junio de 2016, y acabo [...]
As posted in the ASCO Daily News, Dr. George Demetri, has received recognition for his work in developing targeted TKIs for GIST.
Although the ASCO (American Society for Clinical Oncology) will be a virtual meeting this year, The Life Raft Group continues to be at the forefront in collaborating in efforts to improve treatment for cancer patients. This year, two important abstracts will be presented online that illustrate these efforts.
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
As research regarding GIST and other relevant topics is extensive and dynamic, consensus among the Real World Evidence Team was that it would be a good idea to convene a group tasked with monitoring and assessing this research. Recently the LRG held its inaugural virtual meeting of the newly formed LRG Science Forum.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
Our Rare Disease Day offering is a whitepaper titled 'Partnership for Survival – Treating the Rarest of the Rare' detailing how a collaboration with the NIH has become a model for other advocacy groups and researchers.